ENSYSCE BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
ENSYSCE BIOSCIENCES INC. - More news...
ENSYSCE BIOSCIENCES INC. - More news...
- Ensysce Biosciences Reports Third Quarter 2024 Financial Results
- Ensysce Biosciences Receives Positive Nasdaq Listing Determination
- Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
- Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
- Ensysce Biosciences Receives Notice from Nasdaq
- Ensysce Biosciences Presenting at Upcoming Meetings
- Ensysce Biosciences Submits Phase 3 Protocol to the FDA
- Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
- Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
- Ensysce Biosciences Announces IRB Approval for Key MPAR Study
- Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
- Ensysce Biosciences Regains Compliance with Nasdaq
- Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
- Ensysce Biosciences Reports First Quarter 2024 Financial Results
- Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
- Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
- Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
- Ensysce Biosciences to Participate in Upcoming Industry Events
- Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
- Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering
- Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR
- Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022
- Ensysce Biosciences Announces Results of Special Meeting of Stockholders
- Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting
- Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline
- Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences
- Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103
- Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call
- Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results
- Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing
